Literature DB >> 19296223

Top manager effects on buprenorphine adoption in outpatient substance abuse treatment programs.

Peter D Friedmann1, Lan Jiang, Jeffrey A Alexander.   

Abstract

To examine the influence of top managers' characteristics on the adoption of buprenorphine for opioid dependence among U.S. outpatient substance abuse treatment units, this investigation analyzed a cross-sectional national study of 547 such units in the 2004-2005 wave of the Drug Abuse Treatment System Survey. Administrators reported their demographics, training, and treatment orientation, as well as features of the unit and its pattern of use of buprenorphine. Nationally, 15.8% of programs offered any buprenorphine services. Greater adoption of buprenorphine correlated with directors' younger age, longer tenure, male gender, and weaker endorsement of abstinence as the most important treatment goal. Availability of naltrexone and medical services also correlated positively with buprenorphine adoption. The authors conclude that leaders' characteristics are related to the adoption of innovative practices in addiction treatment programs. Future work should examine whether leadership development for community addiction programs might speed up the diffusion of buprenorphine and other innovative, evidence-based practices.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19296223      PMCID: PMC3682405          DOI: 10.1007/s11414-009-9169-z

Source DB:  PubMed          Journal:  J Behav Health Serv Res        ISSN: 1094-3412            Impact factor:   1.505


  33 in total

1.  A conceptual framework for transferring research to practice.

Authors:  D Dwayne Simpson
Journal:  J Subst Abuse Treat       Date:  2002-06

2.  Trends in comprehensive service availability in outpatient drug abuse treatment.

Authors:  Peter D Friedmann; Stephenie C Lemon; Elizabeth M Durkin; Thomas A D'Aunno
Journal:  J Subst Abuse Treat       Date:  2003-01

3.  Characteristics of opinion leaders in substance abuse treatment agencies.

Authors:  Kathleen A Moore; Roger H Peters; Holly A Hills; James B LeVasseur; Alexander R Rich; W Michael Hunt; M Scott Young; Thomas W Valente
Journal:  Am J Drug Alcohol Abuse       Date:  2004       Impact factor: 3.829

4.  Optimizing opioid detoxification: rearranging deck chairs on the Titanic.

Authors:  Michael D Stein; Peter D Friedmann
Journal:  J Addict Dis       Date:  2007

5.  Innovation adoption in substance abuse treatment: exposure, trialability, and the Clinical Trials Network.

Authors:  Lori J Ducharme; Hannah K Knudsen; Paul M Roman; J Aaron Johnson
Journal:  J Subst Abuse Treat       Date:  2007-02-22

6.  Adoption and implementation of new technologies in substance abuse treatment.

Authors:  Paul M Roman; J Aaron Johnson
Journal:  J Subst Abuse Treat       Date:  2002-06

7.  Improving the organization, management, and outcomes of substance abuse treatment programs.

Authors:  Carolyn J Heinrich; Laurence E Lynn
Journal:  Am J Drug Alcohol Abuse       Date:  2002-11       Impact factor: 3.829

Review 8.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

Authors:  R P Mattick; C Breen; J Kimber; M Davoli
Journal:  Cochrane Database Syst Rev       Date:  2002

9.  Changes in methadone treatment practices: results from a national panel study, 1988-2000.

Authors:  Thomas D'Aunno; Harold A Pollack
Journal:  JAMA       Date:  2002-08-21       Impact factor: 56.272

Review 10.  Pharmacologic treatments for opioid dependence: detoxification and maintenance options.

Authors:  Herbert D Kleber
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

View more
  21 in total

1.  Timing of buprenorphine adoption by privately funded substance abuse treatment programs: the role of institutional and resource-based interorganizational linkages.

Authors:  Sarah A Savage; Amanda J Abraham; Hannah K Knudsen; Tanja C Rothrauff; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2011-08-09

2.  Managerial capacity and adoption of culturally competent practices in outpatient substance abuse treatment organizations.

Authors:  Erick G Guerrero
Journal:  J Subst Abuse Treat       Date:  2010-08-21

3.  Adoption and implementation of medications in addiction treatment programs.

Authors:  Hannah K Knudsen; Amanda J Abraham; Paul M Roman
Journal:  J Addict Med       Date:  2011-03       Impact factor: 3.702

4.  A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment.

Authors:  Traci R Rieckmann; Anne E Kovas; Bentson H McFarland; Amanda J Abraham
Journal:  J Subst Abuse Treat       Date:  2011-08-06

5.  Financial factors and the implementation of medications for treating opioid use disorders.

Authors:  Hannah K Knudsen; Paul M Roman
Journal:  J Addict Med       Date:  2012-12       Impact factor: 3.702

6.  The transition to medication adoption in publicly funded substance use disorder treatment programs: organizational structure, culture, and resources.

Authors:  Hannah K Knudsen; Paul M Roman
Journal:  J Stud Alcohol Drugs       Date:  2014-05       Impact factor: 2.582

7.  Pharmacotherapy, Resource Needs, and Physician Recruitment Practices in Substance Use Disorder Treatment Programs.

Authors:  Hannah K Knudsen; Randy Brown; Nora Jacobson; Julie Horst; Jee-Seon Kim; Elizabeth Collier; Sanford Starr; Lynn M Madden; Eric Haram; Todd Molfenter
Journal:  J Addict Med       Date:  2019 Jan/Feb       Impact factor: 3.702

8.  Organizational capacity for service integration in community-based addiction health services.

Authors:  Erick G Guerrero; Gregory A Aarons; Lawrence A Palinkas
Journal:  Am J Public Health       Date:  2014-02-13       Impact factor: 9.308

9.  Organizational implementation of evidence-based substance abuse treatment in racial and ethnic minority communities.

Authors:  Erick G Guerrero; Amy He; Ahraemi Kim; Gregory A Aarons
Journal:  Adm Policy Ment Health       Date:  2014-11

10.  A comparison of buprenorphine and psychosocial treatment outcomes in psychosocial and medical settings.

Authors:  Ned J Presnall; D A Patterson Silver Wolf; Derek S Brown; Sara Beeler-Stinn; Richard A Grucza
Journal:  J Subst Abuse Treat       Date:  2019-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.